Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix, Inc - Superlative Performance in Rare Diseases

Come join the Family Office Networks’ Webinar Series featuring Soligenix, Inc.
 
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
 
The Focus:
 
A Specialized BioTherapeutics business segment dedicated to the development of products for orphan diseases and areas of unmet medical need in oncology and inflammation.
 
A Public Health Solutions business segment, funded entirely by the US Government to the amount of approximately $70 million to date, developing vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, emerging and antibiotic resistant infectious disease, and viral disease including Ebola, Marburg and COVID-19.
 
Nasdaq: SNGX Stock Snapshot as of 10/01/20 Market Cap: ~ $53.7 Million Stock Price: $1.80 Avg Daily Vol (50D): ~ 1.1M Shares Outstanding: ~ 29.8 Million